Articles tagged "Immunosuppression"

2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
C. Schardt, R. Yau, A. Burgos, C. Tunwar
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…
2020 American Transplant Congress
Pre-Transplant Pharmacogenetics Identifies CYP3A4 and CYP3A5 Heterogeneity among Caucasian Kidney Transplant Recipients
N. Oliver¹, L. Lindberg¹, S. LeCorchick¹, D. Morris¹, S. Anand¹, T. Srinivas²
¹Intermountain Medical Center, Murray, UT, ²University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Tacrolimus has always been dosed based on therapeutic drug monitoring, however pharmacogenomics is becoming increasingly more utilized in the era of precision based medicine…
2020 American Transplant Congress
Targeting Th17: TIGIT as a Key Regulator of Tregs/Th17 Cells in Belatacept Resistant Rejection
C. R. Hartigan, M. Wagener, M. L. Ford
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Belatacept resistant-rejection (BRR) is a major barrier to the widespread adoption of immune checkpoint blockade therapeutics in transplantation. Our lab has shown that patients…
2020 American Transplant Congress
Sirolimus Plus Tacrolimus Immunosuppression, with or without Mycophenolate Mofetil, May Improve Survival after Bronchiolitis Obliterans Syndrome in Lung Transplant Patients
M. Wijesinha, M. Terrin, B. Griffith, A. Iacono
University of Maryland School of Medicine, Baltimore, MD
*Purpose: There are very few ways to improve survival after bronchiolitis obliterans syndrome (BOS), the leading cause of death in lung transplant patients. Two long-term…
2020 American Transplant Congress
Impact of Extended- versus Immediate-Release Tacrolimus on One-Year Development of De Novo DSA and Chronic Immune Activation in Kidney Transplantation (ASTOUND Study)
A. Wiseman¹, D. Kaufman², A. Patel³, D. Wojciechowski⁴, A. Tambur⁵, J. Kim⁶, J. Schwartz⁶
¹University of Colorado Hospital, Aurora, CO, ²University of Wisconsin, Madison, WI, ³Henry Ford Hospital, Detroit, MS, ⁴Massachusetts General Hospital, Boston, MA, ⁵Northwestern University, Chicago, IL, ⁶Astellas Pharma Global Development, Northbrook, IL
*Purpose: To compare, using an adaptive study design, the 1-year incidence of a novel two-part composite endpoint consisting of de novo donor-specific antibody (dnDSA) formation…
2020 American Transplant Congress
Regulatory T Cells Engineered with TCR-Signaling-Responsive Il-2 Nanogels Suppress Alloimmunity in Sites of Antigen Encounter
S. K. Eskandari¹, J. B. Alhaddad¹, I. Sulkaj², M. B. Melo², N. Li², H. Allos¹, B. Kollar¹, M. A. Seelen³, D. J. Irvine⁴, J. Azzi¹
¹Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Koch Institute for Integrative Cancer Research, Massachusetts Insitute of Technology, Cambridge, MA, ³Nephrology, University Medical Center Groningen, Groningen, Netherlands, ⁴Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Insitute of Technology, Cambridge, MA
*Purpose:
2020 American Transplant Congress
Safety of Belatacept in HIV-Positive Kidney Transplant Recipients
K. El Sakhawi¹, A. Scemla², D. Bertrand³, C. Garrouste⁴, P. Malvezzi⁵, P. Grimbert¹, M. Matignon¹
¹Nephrology, APHP Henri Mondor, Créteil, France, ²Nephrology, APHP Necker Enfants Malades, Paris, France, ³Nephrology, CHU Bois Guillaume, Rouen, France, ⁴Nephrology, CHU Clermond Ferrand, Clermont Ferrand, France, ⁵Nephrology, CHU Grenoble, Grenoble, France
*Purpose: Kidney allograft survival in HIV-infected patients is lower than in the general population. Belatacept (instead of anticalcineurins (CNI)) has been shown to have a…
2020 American Transplant Congress
Evaluation of the Use of Sublingual Tacrolimus in the Inpatient Setting
K. Szempruch¹, L. Kemp¹, A. Barber¹, S. Mason¹, G. Offei-Nkansah¹, D. Gerber², P. Owen¹
¹Pharmacy, UNC Medical Center, Chapel Hill, NC, ²Surgery-Transplant, UNC Medical Center, Chapel Hill, NC
*Purpose: To determine the efficacy and safety of sublingual (SL) tacrolimus (TAC) administration.*Methods: A single-center, retrospective study was performed on solid organ transplant recipients who…
2020 American Transplant Congress
Clinical Implications of Tacrolimus Time in Therapeutic Range in Urban Renal Transplant Recipients Under an Early Corticosteroid Withdrawal Protocol
D. Pierce, P. West-Thielke, Z. Hajjiri, S. Gaitonde, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus displays wide inter- and intra-patient variability, necessitating therapeutic drug monitoring. Assessing the duration of time in therapeutic range (TTR) is an additional tool…
2020 American Transplant Congress
Evaluation of Optimization of Workflow for Timing of Inpatient Therapeutic Drug Monitoring of Maintenance Immunosuppressive Drugs in Abdominal Transplant Recipients
J. Schulte, S. Mehta, E. Vargas, K. Cunningham
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Therapeutic drug monitoring (TDM) is essential to the safety and efficacy of immunosuppressants (IS) given their narrow therapeutic index. After an internal review, it…